Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments.
Novo Nordisk’s Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed
Where Today's News Shapes Tomorrow
